Common Sensing Announces Kevin Schmid as Chief Operating Officer

Monday, January 8, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Schmid's drug delivery, diabetes, and medical device successes to be brought to bear on Common Sensing injector monitoring solutions.

CAMBRIDGE, Mass., Jan. 8, 2018 /PRNewswire/ -- Common Sensing, manufacturer of injectable medicine hardware and software

support tools, announced today the appointment of Kevin Schmid as Chief Operating Officer. Mr. Schmid brings extensive business development and operations leadership experience, having previously served in pivotal roles at Insulet Corporation, Bose Corporation, JDS Uniphase, and the Stevanato Group.

"Kevin's addition to the Common Sensing team represents our commitment to meet the market demand for supporting users of injectable medicine," said James White, Common Sensing President. "With a rapidly growing number of Gocap customers for 2018, it is essential to have an industry leader like Kevin Schmid to drive operational excellence and expanded business development efforts."

During his time at Insulet Corporation, Mr. Schmid was instrumental in the development, industrialization, and commercialization of wearable, smart drug delivery pumps, such as the Omnipod Diabetes Management System, the Amgen Neulasta On Body Injector, and the Ferring Pharmaceutical LutrePulse System. Millions of patients who do not prefer—or do not have access to—these drug delivery pumps continue to rely on disposable injector pens for their medication. These pens lack the modern connectivity and data reporting features of drug delivery pumps, which are critical to treatment quality and improved outcomes for diabetes, infertility, obesity, and other indications.

A member of Common Sensing's board of directors since November of 2015, Kevin is excited to play a more active role in Common Sensing's growth. "Common Sensing's Gocap technology is a tremendous opportunity to bring easy-to-use, cost-effective dose monitoring and reporting solutions to millions of people dosing as outpatients," said Kevin Schmid, Common Sensing Chief Operating Officer.

Kevin Schmid - LinkedIn

About Common Sensing

Common Sensing develops and manufactures data-driven hardware and software solutions for people using injectable medicine. Founded in 2012, Common Sensing has assembled a team of talented designers and engineers to develop Gocap™, the first smart cap that turns existing injector pens into smart injectors. Gocap connects insulin, GLP-1, fertility hormone, and human growth hormone injector pens to the cloud to improve outcomes and make everyday treatment more convenient. Based in Cambridge, MA, Common Sensing's investors include Waterline Ventures, Qualcomm Ventures, and Sanofi.

www.common-sensing.com

Media ContactKelly PavaoT: +1 (774) 488-6458E: contact@common-sensing.com

 

Cision View original content:http://www.prnewswire.com/news-releases/common-sensing-announces-kevin-schmid-as-chief-operating-officer-300578505.html

SOURCE Common Sensing



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store